<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01418794</url>
  </required_header>
  <id_info>
    <org_study_id>SYNH-20101010</org_study_id>
    <nct_id>NCT01418794</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenyang Northern Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenyang Northern Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polymer carried by drug-eluting stents may increase inflammatory response and thrombosis. Our
      previous study showed that polymer-free rapamycin-coated stents brings dose-dependent
      reduction in restenosis. This prospective, multicenter, randomized controlled clinical trials
      aimed to explore efficacy and safety of the YUKON drug eluting stent in diffuse coronary
      artery disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>270-day(+60 days) in-stent late lumen loss(LLL) measured by quantitative coronary angiography (QCA)</measure>
    <time_frame>270 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Restenosis rate in Stent, stent proximal edge, distal edge of stent and the lesion segment</measure>
    <time_frame>270 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite end point of major adverse cardiac events(MACE)</measure>
    <time_frame>30 days, 6 months, 9 months, 1 year</time_frame>
    <description>Composite end point of cardiac death, all Q-wave and non-Q wave myocardial infarction, clinical-driven target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis events after PCI for 24 hours, 30 days and 1 year</measure>
    <time_frame>24 hours, 30 days and 1 year</time_frame>
    <description>according to ARC definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of stent implantation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">606</enrollment>
  <condition>Acute Coronary Syndromes</condition>
  <arm_group>
    <arm_group_label>Low dose rapamycin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concentration of rapamycin was 1.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose rapamycin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concentration of rapamycin is 2.5%</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High dose rapamycin stent</intervention_name>
    <description>Concentration of rapamycin is 2.5%</description>
    <arm_group_label>High dose rapamycin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low dose rapamycin stent</intervention_name>
    <description>Concentration of rapamycin is 1.5%</description>
    <arm_group_label>Low dose rapamycin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18-85 years old, male or nonpregnant women

          -  asymptomatic ischemia, stable or unstable angina, old myocardial infarction patients

          -  at least one target lesion length ≥ 20 mm (Visual method)

          -  Target lesion diameter 2.5mm-4.0 mm (Visual method)

          -  Target lesion diameter stenosis ≥ 70%

          -  Patients who has indications for coronary artery bypass graft (CABG) surgery

          -  Patients who is voluntary, understand the purpose of the study, willing to accept
             angiography and clinical follow-up

        Exclusion Criteria:

          -  Acute myocardial infarction for less than 1 week

          -  Bridge vascular disease

          -  In-stent restenosis lesions

          -  Patient with bleeding tendency, history of active peptic ulcer, History of cerebral
             hemorrhage or subarachnoid hemorrhage, history of stroke within half year,
             contraindications to anticoagulant therapy and antiplatelet

          -  Allergic to aspirin, clopidogrel or ticlopidine, heparin, contrast agent, rapamycin
             and metal

          -  Life expectancy is less than 12 months

          -  Patient who has participated in other clinical trials but does not meet the deadline
             of the primary endpoint

          -  Poor patient compliance

          -  Heart transplant recipient

          -  Patient who had other stent implanted within 1 year

          -  Patient who has multi-vessel disease(Long lesions) and has already received other
             stent implantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ya-Ling Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenyang Northern Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ya-Ling Han, MD</last_name>
    <phone>+86-24-23922184</phone>
    <email>hanyaling.nh@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi Li, MD</last_name>
    <phone>+86-24-23991876</phone>
    <email>doctorliyi@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The 2nd Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Yu, MD</last_name>
      <phone>+86-451-86605346</phone>
      <email>yubodr@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuan-Yu Gao, MD</last_name>
      <phone>+86-371-65580011</phone>
      <email>Gaocy2000@yahoo.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenyang Northern Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Li, MD</last_name>
      <phone>+86-24-28851168</phone>
      <email>doctorliyi@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Armed Police Force Medical College Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300162</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tie-Min Jiang, MD</last_name>
      <phone>+86-22-60578777</phone>
      <email>wjyxyfy@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2011</study_first_submitted>
  <study_first_submitted_qc>August 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2011</study_first_posted>
  <last_update_submitted>August 16, 2011</last_update_submitted>
  <last_update_submitted_qc>August 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Yaling Han, M.D. PhD</name_title>
    <organization>Shenyang Northern Hospital</organization>
  </responsible_party>
  <keyword>Acute Coronary Syndromes</keyword>
  <keyword>Drug eluting stent</keyword>
  <keyword>Diffused lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

